NorthCoast Asset Management LLC Has $500,000 Stock Position in Illumina, Inc. (NASDAQ:ILMN)

NorthCoast Asset Management LLC reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,057 shares of the life sciences company’s stock after selling 107 shares during the quarter. NorthCoast Asset Management LLC’s holdings in Illumina were worth $500,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Illumina by 1.3% in the 1st quarter. Geode Capital Management LLC now owns 2,411,040 shares of the life sciences company’s stock worth $923,443,000 after acquiring an additional 30,415 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Illumina by 2.1% in the 1st quarter. Polen Capital Management LLC now owns 2,377,029 shares of the life sciences company’s stock worth $912,922,000 after acquiring an additional 48,751 shares in the last quarter. Ownership Capital B.V. boosted its holdings in shares of Illumina by 1.9% in the 2nd quarter. Ownership Capital B.V. now owns 1,023,891 shares of the life sciences company’s stock worth $484,515,000 after acquiring an additional 18,946 shares in the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of Illumina by 3.6% in the 1st quarter. Canada Pension Plan Investment Board now owns 731,784 shares of the life sciences company’s stock worth $281,049,000 after acquiring an additional 25,475 shares in the last quarter. Finally, DF Dent & Co. Inc. boosted its holdings in shares of Illumina by 0.5% in the 1st quarter. DF Dent & Co. Inc. now owns 696,807 shares of the life sciences company’s stock worth $267,616,000 after acquiring an additional 3,526 shares in the last quarter. 88.56% of the stock is currently owned by institutional investors and hedge funds.

In other Illumina news, SVP Susan H. Tousi sold 300 shares of the stock in a transaction dated Monday, June 28th. The shares were sold at an average price of $478.95, for a total value of $143,685.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Alexander Aravanis sold 539 shares of the stock in a transaction dated Wednesday, July 7th. The shares were sold at an average price of $477.59, for a total transaction of $257,421.01. The disclosure for this sale can be found here. Insiders sold a total of 3,067 shares of company stock valued at $1,491,077 over the last quarter. 0.23% of the stock is currently owned by company insiders.

Several research analysts have recently commented on ILMN shares. SVB Leerink downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $425.00 target price on the stock. in a report on Thursday, August 19th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $504.00 price objective for the company in a research report on Wednesday, June 30th. Robert W. Baird restated a “hold” rating on shares of Illumina in a research report on Sunday, August 22nd. Barclays boosted their price objective on shares of Illumina from $355.00 to $365.00 and gave the stock an “underweight” rating in a research report on Friday, August 6th. Finally, Canaccord Genuity boosted their price objective on shares of Illumina from $515.00 to $555.00 and gave the stock a “buy” rating in a research report on Monday, August 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Illumina has an average rating of “Hold” and an average price target of $432.83.

Shares of NASDAQ ILMN opened at $434.59 on Thursday. The firm has a market cap of $63.75 billion, a PE ratio of 83.25, a PEG ratio of 2.24 and a beta of 0.91. The company has a current ratio of 6.08, a quick ratio of 5.64 and a debt-to-equity ratio of 0.32. Illumina, Inc. has a 1-year low of $267.10 and a 1-year high of $555.77. The company has a fifty day moving average price of $478.65 and a 200 day moving average price of $439.44.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, August 5th. The life sciences company reported $1.87 EPS for the quarter, topping the Zacks’ consensus estimate of $1.36 by $0.51. Illumina had a net margin of 19.36% and a return on equity of 18.12%. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business posted $0.62 EPS. Equities research analysts forecast that Illumina, Inc. will post 6.48 EPS for the current year.

Illumina Company Profile

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Featured Article: How does a reverse stock split work?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.